NAM

Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good practice

Retrieved on: 
Tuesday, February 13, 2024

Chemical giant LyondellBasell (LYB) has emerged as an example of better practice in this field by proactively addressing concerns over misaligned industry affiliations.

Key Points: 
  • Chemical giant LyondellBasell (LYB) has emerged as an example of better practice in this field by proactively addressing concerns over misaligned industry affiliations.
  • The company's Climate Advocacy Report , released in May 2023, evaluates its memberships in key trade associations, categorising each based on alignment with climate policy positions.
  • Another example of good practice is provided by Bayer’s (BAY) Industry Association Climate Review (2023) which assesses 63 associations.
  • As the world grapples with climate challenges, the time for blurred communication is long gone, and corporate leaders should be clear about their climate transition pathway.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Plumbing Manufacturers International Applauds House for Approving 'Tax Relief for American Families and Workers Act'

Retrieved on: 
Friday, February 2, 2024

The measure will enable manufacturers to invest in their businesses, create jobs, and compete in the global marketplace. The bill is particularly important for small- and medium-sized manufacturers, many of which experienced significant tax increases as a result of the expiration of pro-growth provisions. The overwhelming majority -- 89% -- of respondents to the NAM's Q4 Manufacturers' Outlook Survey said higher tax burdens on manufacturing would make it more difficult for them to hire, buy new equipment, and expand their facilities.

Key Points: 
  • Plumbing Manufacturers International applauds the House of Representatives, which voted 357 to 70 on Jan. 31 to approve H.R.
  • 7024, the Tax Relief for American Families and Workers Act of 2024.
  • This bipartisan, bicameral tax framework agreement was developed by House Ways and Means Committee Chairman Jason Smith (R-Missouri) and Senate Finance Committee Chairman Ron Wyden (D-Oregon).
  • 7024 was approved 40 to 3 on Jan. 19 by the House Ways and Means Committee.

NAM Info Inc unveils Telecom services startup: NAM InfoCom

Retrieved on: 
Wednesday, January 31, 2024

CRANBURY, N.J., Jan. 31, 2024 /PRNewswire-PRWeb/ -- NAM Info Inc, a trailblazing technology and information services provider, is thrilled to announce the official launch of NAM InfoCom, a dynamic telecom services startup poised to redefine communication in today's digital landscape. NAM InfoCom offers a suite of innovative communication solutions for enterprises, including three flagship products: eNCALL, eNCOM, and eNWEB, meticulously designed to meet the unique needs and challenges of the modern business landscape.

Key Points: 
  • NAM InfoCom, is a dynamic telecom services startup poised to redefine communication in today'sdigital landscape.
  • CRANBURY, N.J., Jan. 31, 2024 /PRNewswire-PRWeb/ -- NAM Info Inc, a trailblazing technology and information services provider, is thrilled to announce the official launch of NAM InfoCom, a dynamic telecom services startup poised to redefine communication in today's digital landscape.
  • NAM InfoCom offers a suite of innovative communication solutions for enterprises, including three flagship products: eNCALL, eNCOM, and eNWEB, meticulously designed to meet the unique needs and challenges of the modern business landscape.
  • NAM InfoCom has come out with a revolutionary communication framework based on WebRTC technology and ensuring the most important requirement of enterprise which is security.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on: 
Monday, January 22, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
  • “Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
  • Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
  • Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.

2023 Brings Rapid Expansion for ITSM Leader EasyVista

Retrieved on: 
Thursday, January 25, 2024

EasyVista, a global leading provider of ITSM, IT Remote Support and IT Monitoring solutions, experienced another year of rapid growth and expansion—both in terms of ARR and other company initiatives.

Key Points: 
  • EasyVista, a global leading provider of ITSM, IT Remote Support and IT Monitoring solutions, experienced another year of rapid growth and expansion—both in terms of ARR and other company initiatives.
  • In 2023, EasyVista earned the rating of 4.9/5 on the Gartner Peer Insights reviews , with a 95% of users sharing a “willingness to recommend” EasyVista to their peers.
  • These ratings for EasyVista are an increase from 4.7/5 and 83%, respectively, in the 2022 Gartner Peer Insights forum.
  • If 2023, a year of great achievements, is any indication of what’s in store for EasyVista in 2024, the rest of the ITSM industry better watch out.”

Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

Retrieved on: 
Tuesday, January 16, 2024

Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.

Key Points: 
  • Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.
  • Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this funding includes a $3.8 million credit facility.
  • Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2.
  • Lynn Durham, CEO of Stalicla commented: “This financial backing underscores Stalicla's role as a trailblazer in the neuro precision space with first applications in precision psychiatry.

Vensure Employer Solutions Appoints Pat Cleary as Chief Growth Officer and Board Member

Retrieved on: 
Tuesday, January 16, 2024

Vensure Employer Solutions , a leading provider of HR/HCM technology, managed services, and global business process outsourcing, today announced the appointment of Pat Cleary as Chief Growth Officer and member of Vensure’s Board of Directors.

Key Points: 
  • Vensure Employer Solutions , a leading provider of HR/HCM technology, managed services, and global business process outsourcing, today announced the appointment of Pat Cleary as Chief Growth Officer and member of Vensure’s Board of Directors.
  • Cleary is the former president and CEO of the National Association of Professional Employer Organizations (NAPEO), the leading trade association for the PEO industry, where he served from 2011-2023.
  • By unifying PEOs to focus on education, promotion and growth, the industry quadrupled in size during his tenure with NAPEO.
  • “I’m honored to be joining the Vensure Employer Solutions organization during this period of enormous growth,” Cleary stated.

Addex to Present at Biotech Showcase™ 2024

Retrieved on: 
Friday, January 5, 2024

For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .

Key Points: 
  • For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders.
  • Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 14, 2023

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update.
  • “The third quarter marked the first patients receiving Omisirge following FDA approval and the point at which Gamida Cell truly transitioned to a commercial-stage company with our first revenue reported,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • The company reported revenue for the delivery of two units of Omisirge in the third quarter of 2023 and projects revenue from a total of four to six units for full year 2023.
  • Annual shareholders meeting: Gamida Cell held its Annual General Meeting of Shareholders in New York City on October 19.